Appointment of Internal Auditor
GKSL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gujarat Kidney and Super Speciality Ltd (GKSPL) reported strong full-year FY2026 results with consolidated revenue from operations more than doubling to Rs 8,201.34 Lacs (FY2025: Rs 4,024.21 Lacs), representing 103.8% YoY growth. Consolidated PAT grew 77% to Rs 1,681.18 Lacs (FY2025: Rs 949.94 Lacs). Standalone revenue grew 14% to Rs 4,010.02 Lacs and PAT increased 8.7% to Rs 990.14 Lacs. The company also appointed Mr Siddharth Atulbhai Shah as Internal Auditor for FY2026-27 (a CA with 7 years experience in Assurance, Internal Audit, and Forensic & Fraud Risk) and SPANJ & Associates as Secretarial Auditor for five years. The Board deferred the CEO appointment agenda and announced a postal ballot for shareholder approval of variation in objects of the IPO. The auditor issued an unmodified opinion on standalone results, though the consolidated results audit relied on other auditors' reports for 8 subsidiary entities (including Raj Patel Hospital, Gujarat Surgical Hospital, Harmony Medicare, Parekh's Hospital, among others). Cash flow from operations was negative for both standalone (Rs -745.86 Lacs) and consolidated (Rs -386.17 Lacs), driven largely by large increases in trade receivables and advance payments.
Strong top-line and bottom-line growth on the back of subsidiary consolidation; however, negative operating cash flows and the deferred CEO appointment are concerns that warrant monitoring. The postal ballot for IPO object variation suggests potential change in use of IPO proceeds.